MedTrace Logo

Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis

NCT07243639 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-11

No results posted yet for this study

Summary

Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.

Conditions

  • Ulcerative Colitis (Disorder)

Interventions

DRUG

Etrasimod administration

2 mg of Etrasimod is orally administered everyday.

Sponsors & Collaborators

  • Showa Inan General Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07243639 on ClinicalTrials.gov